Get the Stockscreener App
3.12
2.80%
-0.09
After Hours:
3.20
0.08
+2.56%
Aclarion Inc stock is traded at $3.12, with a volume of 25,225.
It is down -2.80% in the last 24 hours and down -0.95% over the past month.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
See More
Previous Close:
$3.21
Open:
$3.1734
24h Volume:
25,225
Relative Volume:
0.27
Market Cap:
$7.68M
Revenue:
$77,900
Net Income/Loss:
$-8.05M
P/E Ratio:
-0.338
EPS:
-9.2296
Net Cash Flow:
$-7.47M
1W Performance:
-12.61%
1M Performance:
-0.95%
6M Performance:
-51.55%
1Y Performance:
-57.89%
1-Day Range:
$3.12
$3.30
1-Week Range:
$3.11
$3.54
52-Week Range:
$2.3401
$12.03
Aclarion Inc Stock (ACON) Company Profile
Name
Aclarion Inc
Sector
Industry
Phone
833 275 2266
Address
8181 ARISTA PLACE, BROOMFIELD
Compare ACON vs VEEV, BTSG, TEM, HQY, HNGE
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACON
Aclarion Inc
|
3.12 | 7.68M | 77,900 | -8.05M | -7.47M | -9.2296 |
VEEV
Veeva Systems Inc
|
159.54 | 25.92B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
63.23 | 12.41B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
47.82 | 8.59B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
88.34 | 7.39B | 1.34B | 230.70M | 440.96M | 2.6695 |
HNGE
Hinge Health Inc
|
65.34 | 5.06B | 646.34M | -512.40M | 202.76M | -6.6871 |
Aclarion Inc Stock (ACON) Latest News
Aclarion (ACON) Chief Strategy Officer granted 55,000 RSUs vesting in 2027 - Stock Titan
Aclarion (ACON) director receives 20,000 RSUs vesting in 2027 - Stock Titan
Aclarion (NASDAQ: ACON) director receives 20,000 RSU equity grant - Stock Titan
Aclarion (ACON) CFO awarded 50,000 restricted stock units set to vest 2027 - Stock Titan
Aclarion (ACON) CEO Brent Ness receives 100,000 RSU equity award - Stock Titan
Aclarion (ACON) director awarded 20,000 RSUs vesting in 2027 - Stock Titan
Aclarion (ACON) grants 100,000 RSUs to Executive Chairman Thramann - Stock Titan
Aclarion (ACON) director receives 20,000 RSU equity award, total holdings 22,502 shares - Stock Titan
Director granted 20,000 RSUs at Aclarion (NASDAQ: ACON) vesting 2027 - Stock Titan
Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform - Ortho Spine News
Aclarion Inc. (ACON) Consolidates Near Key Support After Marginal DeclinePrice Target - newsline.com
Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub - Yahoo Finance
Aclarion Company Profile & Introduction - Moomoo
Aclarion partners with PRIA Healthcare on market access program By Investing.com - Investing.com South Africa
Aclarion partners with PRIA Healthcare on market access program - Investing.com
Aclarion enlists PRIA in push for insurer coverage of AI back-pain scans - Stock Titan
Aclarion waves off investor’s acquisition offer - BizWest
Echo Lake Capital cancelled the acquisition of Aclarion, Inc.. - marketscreener.com
Aclarion Comments on Echo Lake News - Baystreet.ca
Aclarion board rejects Echo Lake’s $4 per share takeover bid By Investing.com - Investing.com Australia
Aclarion board rejects Echo Lake’s $4 per share takeover bid - Investing.com
Aclarion Rejects Echo Lake Capital’S Unsolicited Acquisition Proposal - TradingView
Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal - The Manila Times
Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting - The Manila Times
Aclarion board: Echo Lake’s $4 bid uses company cash, favors buyer - Stock Titan
Back pain tech Aclarion cites 196% scan growth as investors back board - Stock Titan
Aclarion rejects unsolicited $4/share buyout proposal - grafa.com
Aclarion, Inc. 8-K SEC Filing June 2026 – Equity Incentive Plan Amendment Approved and Company Information - Minichart
Aclarion Stockholders Approve Directors and Equity Plan Amendment - TipRanks
Aclarion (ACON) shareholders elect board, ratify auditor and approve equity plan - Stock Titan
Aclarion partners with Los Angeles neuroscience clinic for study By Investing.com - Investing.com Australia
Aclarion partners with Institute of Neuro Innovation to expand Nociscan use for chronic low back pain diagnosis. - Pluang
Aclarion partners with Los Angeles neuroscience clinic for study - Investing.com
Aclarion Expands Nociscan Availability in Greater Los Angeles Through Partnership with Institute of Neuro Innovation - Quiver Quantitative
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation - marketscreener.com
Back-pain scan Nociscan helps pinpoint bad discs, now in L.A. - Stock Titan
Aclarion's Nociscan tech reveals immune-linked back pain subtypes, expanding precision spine care potential. - Pluang
Aclarion’s Technology Shows Potential in Identifying Immune-Biomarkers in New Study - geneonline.com
Aclarion’s Nociscan technology used in back pain study By Investing.com - Investing.com South Africa
Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study - The Manila Times
Aclarion's Nociscan Technology Linked to Immune Signatures in Back Pain Study, Expanding Clinical Applications - Quiver Quantitative
Aclarion’s Nociscan technology used in back pain study - Investing.com
ACON Maintained by Ascendiant Capital -- Price Target Raised to $7.50 - GuruFocus
SentinelOne To Rally Nearly 40%? Here Are 10 Analyst Forecasts For Friday - Benzinga
Aclarion Inc. Warrants (ACONW) Edge Lower as Tight Trading Range Persists at $0.03Algorithmic Stock Picks - The Legal Advocate
Aclarion: Board Will Determine Course of Action It Believes Is in Best Interests of Co, Hldrs >ACON - Moomoo
Aclarion to Review Echo Lake Capital’s Unsolicited Proposal - geneonline.com
Aclarion: Echo Lake Communication Contains Numerous Assertions Regarding Governance and Other Matters That Lack Important Context >ACON - Moomoo
Aclarion: Echo Lake Cap Offered to Acquire the Co for $4/Shr in Cash and Contingent Value Rights >ACON - Moomoo
Aclarion, Inc. Comments on Echo Lake Capital’s Letter and Unsolicited Proposal - The Manila Times
Aclarion, Inc. Responds to Echo Lake Capital's Acquisition Proposal and Reaffirms Commitment to Shareholder Value - Quiver Quantitative
Aclarion Inc Stock (ACON) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aclarion Inc Stock (ACON) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Neal David K | Director |
May 11 '26 |
Buy |
3.10 |
2,500 |
7,750 |
2,502 |
| Ness Brent | Chief Executive Officer |
May 11 '26 |
Buy |
3.18 |
6,289 |
19,999 |
6,300 |
| Wesemann William | Director |
May 06 '26 |
Buy |
3.30 |
1,562 |
5,155 |
1,563 |
| Ness Brent | Chief Executive Officer |
Nov 26 '25 |
Buy |
6.20 |
10 |
62 |
11 |
0.30%
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):